Gilead Sciences (GILD) - The company announced that a phase 3 NASH study for key asset selonsertib failed to meet its primary endpoint. Dubbed STELLAR-3, the trial was investigating the oral inhibitor of ASK1 in patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis. The pre-specified endpoint was one-stage or greater of histologic improvement in fibrosis without worsening of NASH (by week 48). Not only was this an abject failure, but also the reverse dose response is alarming as well (9.3% of patients on 18mg dose and 12.1% on 6mg dose achieved primary